Skip to content

Research at St Andrews

MDR/XDRTB: What are the new treatment options?

Research output: Contribution to journalReview article

Abstract

Concerns are increasing that the drugs we have used to treat this chronic pulmonary infection will cease to work because of development of resistance, raising the threat of untreatable disease. This review explains the molecular and clinical basis of resistance. The current best practice for the treatment of multi-drug resistance is described. There are a number of new drugs and regimens currently under investigation and these are described. The importance of improved case finding, diagnosis and early treatment are emphasised.

Close

Details

Original languageEnglish
Pages (from-to)211-216
Number of pages6
JournalCurrent Respiratory Medicine Reviews
Volume9
Issue number3
DOIs
Publication statusPublished - 27 Nov 2013

    Research areas

  • Antibiotic resistance, Drug treatment, Extremely drug resistant, Multidrug resistance, Tuberculosis

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

Related by journal

  1. New drugs and treatment regimens

    Sloan, D. J., Davies, G. R. & Khoo, S. H., 2013, In : Current Respiratory Medicine Reviews. 9, 3, p. 200-210 11 p.

    Research output: Contribution to journalArticle

ID: 259231950